ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
08/24/201618:20:00Mylan Faces Scrutiny Over EpiPen Price Increases
08/24/201616:45:41Statement of Changes in Beneficial Ownership (4)
08/24/201616:34:17Initial Statement of Beneficial Ownership (3)
08/23/201617:03:35Current Report Filing (8-k)
08/23/201616:56:43Current Report Filing (8-k)
08/23/201603:03:00New CFO Tops Off Shake-Up At Valeant -- WSJ
08/23/201601:00:00Pharming Convene an Extraordinary General Meeting of Shareholders
08/23/201601:00:00Pharming Convene an Extraordinary General Meeting of Shareholders
08/22/201615:32:00Valeant Names Zoetis Executive as Financial Chief--Update
08/22/201615:30:00Valeant Names Zoetis Executive as Financial Chief--Update
08/22/201610:44:00Valeant Names Zoetis Executive as Financial Chief--Update
08/22/201607:30:00Valeant Names Zoetis Executive as CFO
08/22/201607:10:00Valeant Names Zoetis Executive as CFO
08/22/201606:00:00Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive...
08/22/201606:00:00Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive...
08/22/201603:03:00Valeant to Tap New CFO, As Shake-Up Continues -- WSJ
08/21/201622:10:00Valeant Hiring Paul Herendeen as New CFO
08/19/201603:04:00Valeant Makes Deal To Loosen Debt Terms -- WSJ
08/18/201616:29:00Valeant Again Able to Loosen Debt Terms -- 6th Update
08/18/201614:43:00Valeant Again Able to Loosen Debt Terms -- 5th Update

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad